Thursday, 15 October 2026European Markets

FLEX LNG And TOTALENERGIES Have A High Dividend Yield And Return On Equity In The Energy Sector.

Loading stream...

(vianews) - flex lng (flng.ol) is among this list of stock assets with the highest dividend rate and return on equity on the energy sector.

financial asset price forward dividend yield return on equity
flex lng (flng.ol) kr344.20 9.87% 16.13%
totalenergies (tte.pa) €64.06 4.7% 16.66%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. flex lng (flng.ol)

9.87% forward dividend yield and 16.13% return on equity

flex lng ltd., together with its subsidiaries, engages in the seaborne transportation of liquefied natural gas (lng) worldwide. the company owns and operates vessels with m-type electronically controlled gas injection lng carriers; and vessels with generation x dual fuel propulsion systems. it also provides chartering services. flex lng ltd. was incorporated in 2006 and is based in hamilton, bermuda.

earnings per share

as for profitability, flex lng has a trailing twelve months eps of kr29.86.

pe ratio

flex lng has a trailing twelve months price to earnings ratio of 11.53. meaning, the purchaser of the share is investing kr11.53 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.13%.

more news about flex lng.

2. totalenergies (tte.pa)

4.7% forward dividend yield and 16.66% return on equity

totalenergies se, a multi-energy company, produces and markets fuels, natural gas, and electricity in france, rest of europe, north america, africa, and internationally. it operates through integrated gas, renewables & power; exploration & production; refining & chemicals; and marketing & services segments. the integrated gas, renewables & power segment engages in integrated gas, including liquified natural gas (lng), and low carbon electricity businesses; and upstream and midstream lng activities. its exploration & production segment offers carbon storage and nature-based solutions. the refining & chemicals segment provides refining, petrochemicals, and specialty chemicals; and supply and trading of oil, and marine shipping services. its marketing & services segment engages in the supply and marketing of petroleum products. totalenergies se was formerly known as total se and changed its name to totalenergies se in june 2021. the company was founded in 1924 and is headquartered in courbevoie, france.

earnings per share

as for profitability, totalenergies has a trailing twelve months eps of €7.39.

pe ratio

totalenergies has a trailing twelve months price to earnings ratio of 8.67. meaning, the purchaser of the share is investing €8.67 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.66%.

moving average

totalenergies's worth is above its 50-day moving average of €60.99 and way above its 200-day moving average of €57.10.

more news about totalenergies.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com